Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252312787 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Marija Petrovic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), Faculty of Science, University of Geneva, 1206 Geneva, Switzerland. Hauptthemen laut MEDLINE: MicroRNAs, Glioblastoma, Nucleotides, Cyclic, Macrophages. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PW was funded by CARIGEST SA, CARIGEST SA.
Abstract (Originalsprache)
Glioblastoma (GBM) is an aggressive brain cancer with a highly immunosuppressive tumor microenvironment (TME), invariably infiltrated by tumor-associated macrophages (TAMs). These TAMs resemble M2 macrophages, which promote tumor growth and suppress immune responses. GBM cells secrete extracellular vesicles (EVs) containing microRNA-25, which inhibits the cGAS-STING pathway and prevents TAMs from adopting a pro-inflammatory M1 phenotype. This study characterizes antimiR-25/cGAMP nanocomplexes (NCs) for potential therapeutic applications. A particle size analysis revealed a significant reduction upon complexation with antimiR-25, resulting in smaller, more stable nanoparticles. Stability tests across pH levels (4–6) and temperatures (25–37 °C) demonstrated their resilience in various biological environments. Biological assays showed that antimiR-25 NCs interacted strongly with transferrin (Tf), suggesting potential for blood–brain barrier passage. The use of cGAMP NCs activated the cGAS-STING pathway in macrophages, leading to increased type I IFN (IFN-β) production and promoting a shift from the M2 to M1 phenotype. The combined use of cGAMP and antimiR-25 NCs also increased the expression of markers involved in M1 polarization. These findings offer insights into optimizing antimiR-25/cGAMP NCs for enhancing immune responses in GBM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), Faculty of Science, University of Geneva, 1206 Geneva, Switzerland.
- Translational Research Center in Onco-Hematology (CRTOH), Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland.
ORCID-Profile: Marija Petrovic, Oliwia B Majchrzak, Paul R Walker, Gerrit Borchard, Olivier Jordan
Förderung
- PW was funded by CARIGEST SA
- CARIGEST SA
Zitieren
APA
Petrovic, M., Majchrzak, O. B., Marecar, R. A. M. H., Laingoniaina, A. C., Walker, P. R., Borchard, G., Jordan, O., & Tankov, S. (2024). Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252312787
Vancouver
Petrovic M, Majchrzak OB, Marecar RAMH, Laingoniaina AC, Walker PR, Borchard G, et al. Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252312787
BibTeX
@article{Petrovic2024,
author = {Petrovic, Marija and Majchrzak, Oliwia B and Marecar, Rihana Amreen Mohamed Hachime and Laingoniaina, Annick C and Walker, Paul R and Borchard, Gerrit and Jordan, Olivier and Tankov, Stoyan},
title = {Combining antimiR-25 and cGAMP Nanocomplexes Enhances Immune Responses via M2 Macrophage Reprogramming},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252312787}
}
EUVIMED